-
Bitcoin Bull Anthony Pompliano Launches SPAC Targeting Financial Services: 'My Reputation's On This'
Wednesday, May 21, 2025 - 4:55pm | 1167Entrepreneur, investor and Bitcoin (CRYPTO: BTC) bull Anthony Pompliano has a new SPAC targeting the financial services sector and perhaps a company dealing with cryptocurrency. While the SPAC could target the cryptocurrency space, Pompliano said that's not a definite yes. The SPAC: Pompliano took...
-
Jim Cramer: The Pharmaceutical 'Good Guys' Need To Stand Up
Thursday, September 22, 2016 - 11:07am | 349Jim Cramer is no fan of Mylan NV (NASDAQ: MYL) and how it handled the EpiPen controversy. Cramer ranted on Thursday's "Squawk Box" that EpiPen has to be a "much bigger source" of Mylan's profit than the company is letting on and he would like to see the company's...
-
Allergan's Tobira Acquisition Represents The Highest Premium Ever Paid In Biopharma
Wednesday, September 21, 2016 - 7:21am | 373Allergan plc Ordinary Shares (NYSE: AGN) paid a hefty premium of 159 percent to acquire Vitae Pharmaceuticals Inc (NASDAQ: VTAE) last week, but that figure pales in comparison to the premium attached to its acquisition of Tobira Therapeutics Inc (NASDAQ: TBRA). Allergan will pay $533 million in...
-
Tobira Therapeutics Up 760% Following Allergan Buyout, Liver Drug A Key Focus
Tuesday, September 20, 2016 - 10:29am | 365Tobira Therapeutics Inc (NASDAQ: TBRA), a clinical-stage bio-pharmaceutical company that focuses on the development of therapies to treat non-alcoholic steatohepatitis (NASH) and other liver diseases, soared higher by more than 760 percent on Tuesday after the company agreed to sell itself to...
-
11 Biopharma CEOs To Follow On Twitter
Thursday, August 18, 2016 - 10:52am | 613Twitter Inc (NYSE: TWTR) can be an extremely useful and tradable tool for investors, but only if you follow the right people. Here’s a look at 11 biotech and pharmaceutical company CEOs that have the potential for market-moving tweets. 1. Brent Saunders - @brentlsaunders Saunders is...
-
Allergan Posts Mixed Q2 Results, Guidance Disappoints
Monday, August 8, 2016 - 8:58am | 333Allergan plc Ordinary Shares (NYSE: AGN) announced mixed results as the revenue numbers came below the Street estimate. However, the company's adjusted EPS topped by a penny. Its guidance for the full year also disappointed. The company reported GAAP operating loss from continuing operations of $...
-
Carl Icahn's New Stake In Allergan
Tuesday, May 31, 2016 - 10:16am | 250The billionaire investor confirmed through his Twitter account that he has acquired a "large position" in Allergan plc Ordinary Shares (NYSE: AGN). Shares of Allergan were trading higher by more than 2.5 percent after Tuesday's opening bell. Icahn also said in a statement is he is...
-
Pfizer Announces Merger Termination With Allergan; Will Pay $150 Million Breakup Fee
Wednesday, April 6, 2016 - 7:09am | 378Pfizer Inc. (NYSE: PFE) announced Wednesday morning it has terminated its merger agreement with Allergan plc (NYSE: AGN) following the U.S. Department of Treasury's tax inversion announcement on Monday. Pfizer noted the decision to terminate the merger agreement was mutual. As part of the...
-
Allergan Gains 1.50% Following Q4 Beat, Company Updates On M&A Activity
Monday, February 22, 2016 - 9:51am | 327Shares of Allergan plc Ordinary Shares (NYSE: AGN) were trading higher by more than 1.50 percent on Monday after the company reported its fourth quarter results. Allergan said that it earned $3.41 per share in the fourth quarter on revenue of $4.2 billion. Wall Street analysts were expecting the...
-
Pfizer Buys Allergan In Largest Healthcare Deal Ever
Monday, November 23, 2015 - 10:26am | 733After months of takeover talks, more consolidation in the healthcare space has come to fruition. On Monday morning, Pfizer Inc. (NYSE: PFE) announced it has purchased Allergan PLC (NYSE: AGN) in a deal valued at about $155 billion, the largest ever in the healthcare sector. The transaction is...
-
Top Takeaways From BMO's Specialty Pharma Day
Wednesday, July 1, 2015 - 1:13pm | 583In a report published Wednesday, BMO Capital Markets analyst David Maris discussed key takeaways from a day of meetings with several specialty pharmaceutical companies. Below are some of the highlights of notable presentations. Allergan PLC (NYSE: AGN): The company is planning to work...
-
Ackman: Allergan Is A Good Merger Arbitrage Play, Potential 28% Upside
Thursday, December 18, 2014 - 5:15pm | 421Pershing Square’s CEO Bill Ackman spoke on Bloomberg TV Wednesday, discussing several issues, including Herbalife Ltd.’s (NYSE: HLF) pyramid scheme, Fannie Mae, Freddie Mac, Canadian Pacific Railway Limited (USA) (NYSE: CP), McDonald's Corporation (NYSE: MCD) and Allergan, Inc. (...
-
Will Actavis Win Competition For Allergan's Affection?
Thursday, October 16, 2014 - 11:10am | 839Four pharmaceutical companies have been flirting with merger deals. Discussing the confusing courting, Barron’s called them the Bob & Carol & Ted & Alice of pharmaceuticals, referencing the sexy 1969 comedy-drama with the tag line “Consider the Possibilities.” In...
-
Market Wrap For May 14: Dow's Winning Streak Ends At Five Sessions
Wednesday, May 14, 2014 - 4:47pm | 2536U.S. stocks declined a day after the S&P 500 and Dow indices traded at record-high levels. Investors and traders were likely paying attention to the ten-year Treasury yield which hit 2.5258, the lowest level since late October. The bull market has paused, temporarily at least, until...
-
Forest Labs To Acquire Furiex Pharma A Deal Potentially Worth $1.46 Billion
Monday, April 28, 2014 - 4:44pm | 248This afternoon, Forest Laboratories (NYSE: FRX) said that it would buy Furiex Pharmaceuticals (NASDAQ: FURX) for up to $1.46 billion in cash, and rights. This deal also includes milestone payments to access Furiex's promising treatment for irritable bowel syndrome (IBS). “The acquisition of...